Diabetes

A primer on new drug options

Marc Rendell

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Over the past 20 years, the treatment armamentarium for diabetes has greatly expanded: 8 different classes of non-insulin drugs and 8 different types of insulin are now available. The newer classes of agents include disaccharidase inhibitors, thiazolidinediones, meglitinides, glucagonlike peptide analogs, and dipeptidyl peptidase IV inhibitors. These drugs offer advantages to certain patients when used as add-on (or first-line) therapy; however, metformin remains the preferred first-line oral agent. New long-acting insulin analogs provide more constant basal insulin coverage than neutral protamine Hagedorn (NPH) or lente insulin. Semisynthetic rapid-acting insulins help control prandial hyperglycemia with less risk of postprandial hypoglycemia than is seen with regular insulin. In addition to the many new pharmacological treatments for diabetes, the advent of continuous glucose monitoring permits relatively automated control of insulin pump administration.

Original languageEnglish
Pages (from-to)1113-1127
Number of pages15
JournalConsultant
Volume47
Issue number13
StatePublished - Nov 2007

Fingerprint

Insulin
Pharmaceutical Preparations
Lente Insulin
Long-Acting Insulin
Short-Acting Insulin
Isophane Insulin
Disaccharidases
Dipeptidyl-Peptidase IV Inhibitors
Thiazolidinediones
Metformin
Hypoglycemia
Hyperglycemia
Meals
Therapeutics
Pharmacology
Glucose
Peptides

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Rendell, M. (2007). Diabetes: A primer on new drug options. Consultant, 47(13), 1113-1127.

Diabetes : A primer on new drug options. / Rendell, Marc.

In: Consultant, Vol. 47, No. 13, 11.2007, p. 1113-1127.

Research output: Contribution to journalReview article

Rendell, M 2007, 'Diabetes: A primer on new drug options', Consultant, vol. 47, no. 13, pp. 1113-1127.
Rendell M. Diabetes: A primer on new drug options. Consultant. 2007 Nov;47(13):1113-1127.
Rendell, Marc. / Diabetes : A primer on new drug options. In: Consultant. 2007 ; Vol. 47, No. 13. pp. 1113-1127.
@article{7464299b6eff44dea48a46c05e874eeb,
title = "Diabetes: A primer on new drug options",
abstract = "Over the past 20 years, the treatment armamentarium for diabetes has greatly expanded: 8 different classes of non-insulin drugs and 8 different types of insulin are now available. The newer classes of agents include disaccharidase inhibitors, thiazolidinediones, meglitinides, glucagonlike peptide analogs, and dipeptidyl peptidase IV inhibitors. These drugs offer advantages to certain patients when used as add-on (or first-line) therapy; however, metformin remains the preferred first-line oral agent. New long-acting insulin analogs provide more constant basal insulin coverage than neutral protamine Hagedorn (NPH) or lente insulin. Semisynthetic rapid-acting insulins help control prandial hyperglycemia with less risk of postprandial hypoglycemia than is seen with regular insulin. In addition to the many new pharmacological treatments for diabetes, the advent of continuous glucose monitoring permits relatively automated control of insulin pump administration.",
author = "Marc Rendell",
year = "2007",
month = "11",
language = "English",
volume = "47",
pages = "1113--1127",
journal = "Consultant",
issn = "0010-7069",
publisher = "Cliggott Publishing Co.",
number = "13",

}

TY - JOUR

T1 - Diabetes

T2 - A primer on new drug options

AU - Rendell, Marc

PY - 2007/11

Y1 - 2007/11

N2 - Over the past 20 years, the treatment armamentarium for diabetes has greatly expanded: 8 different classes of non-insulin drugs and 8 different types of insulin are now available. The newer classes of agents include disaccharidase inhibitors, thiazolidinediones, meglitinides, glucagonlike peptide analogs, and dipeptidyl peptidase IV inhibitors. These drugs offer advantages to certain patients when used as add-on (or first-line) therapy; however, metformin remains the preferred first-line oral agent. New long-acting insulin analogs provide more constant basal insulin coverage than neutral protamine Hagedorn (NPH) or lente insulin. Semisynthetic rapid-acting insulins help control prandial hyperglycemia with less risk of postprandial hypoglycemia than is seen with regular insulin. In addition to the many new pharmacological treatments for diabetes, the advent of continuous glucose monitoring permits relatively automated control of insulin pump administration.

AB - Over the past 20 years, the treatment armamentarium for diabetes has greatly expanded: 8 different classes of non-insulin drugs and 8 different types of insulin are now available. The newer classes of agents include disaccharidase inhibitors, thiazolidinediones, meglitinides, glucagonlike peptide analogs, and dipeptidyl peptidase IV inhibitors. These drugs offer advantages to certain patients when used as add-on (or first-line) therapy; however, metformin remains the preferred first-line oral agent. New long-acting insulin analogs provide more constant basal insulin coverage than neutral protamine Hagedorn (NPH) or lente insulin. Semisynthetic rapid-acting insulins help control prandial hyperglycemia with less risk of postprandial hypoglycemia than is seen with regular insulin. In addition to the many new pharmacological treatments for diabetes, the advent of continuous glucose monitoring permits relatively automated control of insulin pump administration.

UR - http://www.scopus.com/inward/record.url?scp=36448943542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36448943542&partnerID=8YFLogxK

M3 - Review article

VL - 47

SP - 1113

EP - 1127

JO - Consultant

JF - Consultant

SN - 0010-7069

IS - 13

ER -